Selective interstitial doxorubicin for recurrent glioblastoma

Clin Case Rep. 2019 Nov 19;7(12):2520-2525. doi: 10.1002/ccr3.2546. eCollection 2019 Dec.

Abstract

Poor delimitation from the viable brain, great genetic heterogeneity, lack of tumor vascularisation are factors that preclude intravenous chemotherapy. Interstitial chemotherapy could be a strategy to avoid a blood-brain barrier and to assure a minimal dose concentration of the chemotherapy agent. Doxorubicin might be devoid of neurotoxic effects and still efficient on remaining far-infiltrated tumor cells.

Keywords: doxorubicin; glioblastoma; interstitial chemotherapy; recurrence; stem cell culture.

Publication types

  • Case Reports